Dr Jonathan Sive

Tel: 0203 447 8028
Email: uclh.uclh.myelomaadminteam@nhs.net

Location:
University College Hospital

Specialities:
Blood Diseases (clinical haematology)

Professional background

Dr Jonathan Sive is a Consultant Haematologist and the Clinical Service Lead for Myeloma at University College London Hospital (UCLH). He is an active member of the UK Myeloma Research Alliance where he is involved in the planning and management of national clinical trials. He is also an executive member of the UK Myeloma Forum where he coordinates myeloma management and guidelines at a national level. He is the chair of the UK national guidelines group for the initial treatment of myeloma.

Dr Sive completed his specialist haematology training at UCLH and carried out a PhD in Molecular Haematology at Cambridge University, for which he was awarded a Cancer Research UK Clinical Fellowship. He remains actively engaged in a variety of clinical research projects and his work has been widely published in peer-reviewed journals and textbooks.

Research interests

Myeloma treatment
Diagnostic techniques in myeloma

Publications

Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. Chavda SJ, Pocock R, Cheesman S, Lee KM, Dowling E, Marks DJB, Kyriakou C, Lee L, Sive J, Wechalekar A, Rabin N, Yong K, Popat R. Br J Haematol. 2020 Jun 14.

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, Jenner M, Henshaw S, Hall R, Sive J, Stern S, Streetly M, Bygrave C, Soutar R, Rabin N, Jackson GH; United Kingdom Myeloma Forum. Br J Haematol. 2020 Jul;190(2):e83-e86. 3

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. Sayar Z, Weatherill A, Keddie S, Sive J, Lunn MP, Thomas M, D'Sa S. Blood Adv. 2020 May 26;4(10):2139-2142.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K. Blood. 2018 ;132(20):2154-2165.

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Blood Cancer J. 2017;7(9):e610.

Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia. Sive JI, Basilico S, Hannah R, Kinston SJ, Calero-Nieto FJ, Göttgens B. Leukemia. 2016 (1):14-23.

Global hypomethylation in myeloma is associated with poor prognosis. Sive JI, Feber A, Smith D, Quinn J, Beck S, Yong K. Br J Haematol. 2016 ;172(3):473-5.

Transcriptional network control of normal and leukaemic haematopoiesis. Sive JI, Göttgens B. Exp Cell Res. 2014 ;329(2):255-64.

Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia. Oram SH, Thoms J, Sive JI, Calero-Nieto FJ, Kinston SJ, Schütte J, Knezevic K, Lock RB, Pimanda JE, Göttgens B. Leukemia. 2013;27(6):1348-57.

Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Sive JI, Thomson KJ, Morris EC, Ward KN, Peggs KS. Clin Infect Dis. 2012;55(10):1362-70.

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience. Sive J, Ardeshna KM, Cheesman S, le Grange F, Morris S, Nicholas C, Peggs K, Statham P, Goldstone AH. Leuk Lymphoma. 2012;53(12):2397-404.

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Br J Haematol. 2012 ;157(4):463-71.

Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. Chavda SJ, Pocock R, Cheesman S, Lee KM, Dowling E, Marks DJB, Kyriakou C, Lee L, Sive J, Wechalekar A, Rabin N, Yong K, Popat R. Br J Haematol. 2020 Jun 14.

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, Jenner M, Henshaw S, Hall R, Sive J, Stern S, Streetly M, Bygrave C, Soutar R, Rabin N, Jackson GH; United Kingdom Myeloma Forum. Br J Haematol. 2020 Jul;190(2):e83-e86. 3

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. Sayar Z, Weatherill A, Keddie S, Sive J, Lunn MP, Thomas M, D'Sa S. Blood Adv. 2020 May 26;4(10):2139-2142.